HUP0302284A2 - Egy triazolo[4,5-d]pirimidin-vegyület új kristályos és amorf formái - Google Patents

Egy triazolo[4,5-d]pirimidin-vegyület új kristályos és amorf formái

Info

Publication number
HUP0302284A2
HUP0302284A2 HU0302284A HUP0302284A HUP0302284A2 HU P0302284 A2 HUP0302284 A2 HU P0302284A2 HU 0302284 A HU0302284 A HU 0302284A HU P0302284 A HUP0302284 A HU P0302284A HU P0302284 A2 HUP0302284 A2 HU P0302284A2
Authority
HU
Hungary
Prior art keywords
amorphous form
triazolo
pyrimidine compound
new crystalline
crystalline
Prior art date
Application number
HU0302284A
Other languages
English (en)
Inventor
Martin Bohlin
Steve Cosgrove
Bo Lassen
Original Assignee
Astrazeneca Ab,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9892841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0302284(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, filed Critical Astrazeneca Ab,
Publication of HUP0302284A2 publication Critical patent/HUP0302284A2/hu
Publication of HUP0302284A3 publication Critical patent/HUP0302284A3/hu
Publication of HU229374B1 publication Critical patent/HU229374B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

A találmány tárgyát az képletű vegyület új formái, különösenkristályos és amorf formái, pontosabban négy kristályos és egy amorfformája, továbbá az ilyen formák előállítására szolgáló eljárás és akristályos és/vagy amorf formát tartalmazó gyógyszerkészítményekképezik. Ó
HU0302284A 2000-06-02 2001-05-31 New crystalline form of a triazolo(4,5-d)pyrimidine compound HU229374B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013407.2A GB0013407D0 (en) 2000-06-02 2000-06-02 Forms of a chemical compound
PCT/SE2001/001239 WO2001092262A1 (en) 2000-06-02 2001-05-31 New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound

Publications (3)

Publication Number Publication Date
HUP0302284A2 true HUP0302284A2 (hu) 2003-10-28
HUP0302284A3 HUP0302284A3 (en) 2007-05-29
HU229374B1 HU229374B1 (en) 2013-11-28

Family

ID=9892841

Family Applications (2)

Application Number Title Priority Date Filing Date
HU1300386A HU230471B1 (hu) 2000-06-02 2001-05-31 Egy triazolo[4,5-d]pirimidin-vegyület új kristályos és amorf formái
HU0302284A HU229374B1 (en) 2000-06-02 2001-05-31 New crystalline form of a triazolo(4,5-d)pyrimidine compound

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU1300386A HU230471B1 (hu) 2000-06-02 2001-05-31 Egy triazolo[4,5-d]pirimidin-vegyület új kristályos és amorf formái

Country Status (36)

Country Link
US (3) US20030181469A1 (hu)
EP (3) EP1493745B2 (hu)
JP (3) JP5036947B2 (hu)
KR (1) KR100781864B1 (hu)
CN (2) CN1817883B (hu)
AR (2) AR032335A1 (hu)
AT (2) ATE320430T1 (hu)
AU (4) AU6287401A (hu)
BG (3) BG65837B1 (hu)
BR (1) BR0111328A (hu)
CA (1) CA2408596C (hu)
CY (1) CY1113047T1 (hu)
CZ (2) CZ304347B6 (hu)
DE (1) DE60117972T2 (hu)
DK (2) DK1289992T3 (hu)
EE (1) EE05222B1 (hu)
ES (2) ES2259031T3 (hu)
GB (1) GB0013407D0 (hu)
HK (2) HK1052347B (hu)
HU (2) HU230471B1 (hu)
IL (4) IL152777A0 (hu)
IS (2) IS2609B (hu)
MX (1) MXPA02011795A (hu)
MY (2) MY148652A (hu)
NO (3) NO323780B1 (hu)
NZ (1) NZ522638A (hu)
PH (1) PH12011000127A1 (hu)
PL (2) PL359172A1 (hu)
PT (2) PT1289992E (hu)
RU (3) RU2325391C2 (hu)
SG (1) SG135965A1 (hu)
SI (2) SI1493745T1 (hu)
SK (1) SK287817B6 (hu)
UA (1) UA73181C2 (hu)
WO (1) WO2001092262A1 (hu)
ZA (1) ZA200209324B (hu)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
JP4298212B2 (ja) * 2002-03-29 2009-07-15 大日本印刷株式会社 塩酸エピナスチン高融点型結晶の製造法
US20080045548A1 (en) * 2006-08-21 2008-02-21 Astrazeneca Ab Pharmaceutical Compositions
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
JP2010508350A (ja) * 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
CN103071154A (zh) * 2007-04-13 2013-05-01 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
KR101669297B1 (ko) 2008-09-09 2016-10-25 아스트라제네카 아베 [1Ｓ-[1-알파,2-알파,3-베타(1Ｓ*,2Ｒ*),5-베타]]-3-[7-[2-(3,4-디플루오로페닐)-사이클로프로필아미노]-5-(프로필티오)-3Ｈ-1,2,3-트리아졸로[4,5-ｄ]피리미딘-3-일]-5-(2-하이드록시에톡시)사이클로펜탄-1,2-디올의 제조 방법 및 그 중간체
US8802850B2 (en) 2009-07-27 2014-08-12 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of P2Y12 receptor
WO2011067571A1 (en) * 2009-12-03 2011-06-09 Astrazeneca Ab Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor
WO2011076749A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Solid pharmaceutical dosage form
CZ2011229A3 (cs) 2011-04-19 2012-08-15 Zentiva, K.S. Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
CN103764149A (zh) 2011-06-01 2014-04-30 阿斯利康(瑞典)有限公司 新型替卡格雷共晶
CN104039792A (zh) * 2011-11-30 2014-09-10 阿特维斯集团公司 替格瑞洛的新结晶形式及其制备方法
US9233966B2 (en) 2012-04-05 2016-01-12 Dr. Reddy's Laboratories Limited Preparation of ticagrelor
WO2014000719A1 (en) * 2012-06-29 2014-01-03 Zentiva, K.S. Novel pharmaceutical solid forms of (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophenyl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyethoxy)cyclopentane-l,2-diol
CA2877541C (en) 2012-07-04 2020-06-30 Lek Pharmaceuticals D.D. Ticagrelor adducts with divalent metal salts
CZ2012705A3 (cs) * 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
CN103772393B (zh) * 2012-10-18 2017-08-04 博瑞生物医药（苏州）股份有限公司 替卡格雷的晶型及其制备方法
WO2014083139A1 (en) * 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Novel amorphous form of ticagrelor
CN103848836B (zh) * 2012-12-07 2016-08-03 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物及其制备方法
WO2014118808A2 (en) * 2013-02-04 2014-08-07 Hetero Research Foundation Ticagrelor solid dispersion
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
WO2014155389A2 (en) * 2013-03-25 2014-10-02 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of ticagrelor
CN104098570A (zh) * 2013-04-07 2014-10-15 杭州领业医药科技有限公司 替卡格雷晶型及其制备方法和用途
CN104098572A (zh) * 2013-04-08 2014-10-15 博瑞生物医药技术(苏州)有限公司 替卡格雷共晶型
CN104098553B (zh) * 2013-04-10 2017-11-28 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP2813216A1 (en) 2013-06-10 2014-12-17 Zentiva, a.s. Stabilized amorphous ticagrelor
WO2014170026A1 (en) 2013-04-18 2014-10-23 Zentiva, K.S. Stabilized amorphous ticagrelor
CA2913326A1 (en) 2013-05-29 2014-12-04 Ratiopharm Gmbh Solid pharmaceutical dosage form
CN104211704B (zh) * 2013-06-03 2017-08-25 杭州领业医药科技有限公司 结晶形态的三唑[4,5‑d]嘧啶化合物及其制备方法和用途
EP3004113A2 (en) * 2013-06-04 2016-04-13 Dr. Reddy's Laboratories Ltd. Preparation of ticagrelor
EP2816043A1 (en) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Spherical ticagrelor particles
WO2015001489A1 (en) * 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Pharmaceutical compositions of ticagrelor
CN104341423B (zh) * 2013-08-02 2017-03-01 上海京新生物医药有限公司 替格瑞洛的一水合物及其制备方法与在制药中的应用
CN104370912A (zh) * 2013-08-13 2015-02-25 开原亨泰制药股份有限公司 替卡格雷多晶型体及其制备方法
IN2013CH04023A (hu) * 2013-09-10 2015-08-07 Laurus Labs Pvt Ltd
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
CN104650085A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 替卡格雷倍半水合物化合物
CN103601726B (zh) * 2013-12-02 2016-09-28 浙江大学 两种替格瑞洛药物共晶及其制备方法
CN104710425B (zh) * 2013-12-16 2019-06-14 石药集团中奇制药技术（石家庄）有限公司 一种替格瑞洛新结晶及其制备方法
CN104650091B (zh) * 2014-01-24 2016-10-05 福州乾正药业有限公司 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用
CN104940204A (zh) * 2014-03-27 2015-09-30 广东东阳光药业有限公司 一种替格瑞洛固体制剂及其制备方法
WO2015162537A1 (en) * 2014-04-23 2015-10-29 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of ticagrelor
WO2015162630A1 (en) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis.
CN105315282B (zh) * 2014-07-15 2018-09-21 博瑞生物医药（苏州）股份有限公司 一种制备替卡格雷无定型的方法
WO2016016907A1 (en) * 2014-08-01 2016-02-04 Msn Laboratories Private Limited Novel polymorphs of (1s,2s,3r,5s)-3-[7-{[(1r,2s)-2-(3,4-difluorophenyl) cyclopropyl]amino}-5-(propylthio)-3h-[1,2,3]-triazolo[4,5-d]pyrimidin-3-yi]-5-(2-hydroxvethoxy) cyclopentane-1,2-diol
WO2016024225A1 (en) * 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Limited Stable amorphous ticagrelor and a process for its preparation
CN104193747B (zh) * 2014-08-12 2016-05-11 许彩霞 替卡格雷无定形的制备
WO2016116942A1 (en) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
CN105968113B (zh) * 2015-03-12 2019-06-07 四川海思科制药有限公司 一种三唑并嘧啶衍生物及其应用
WO2017072790A1 (en) * 2015-10-26 2017-05-04 Avra Laboratories Pvt. Ltd. An improved process for synthesis of ticagrelor
US20190002471A1 (en) * 2016-01-05 2019-01-03 Amneal Pharmaceuticals Company Gmbh Crystalline Form Of Ticagrelor
MA44720A (fr) * 2016-04-21 2019-02-27 Astrazeneca Ab Comprimés à désintégration orale
US10905691B2 (en) 2016-09-09 2021-02-02 Université de Liège Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
ES2731658T3 (es) * 2016-09-09 2019-11-18 Univ Liege Derivados triazolo(4,5-d)pirimidina para uso en la prevención y tratamiento de infección bacteriana
KR101916956B1 (ko) 2016-12-13 2018-11-08 보령제약 주식회사 티카그렐러의 신규한 고체 형태 및 이의 제조방법
WO2018178997A1 (en) 2017-03-31 2018-10-04 Natco Pharma Limited Novel crystalline form of ticagrelor
WO2019127294A1 (zh) * 2017-12-29 2019-07-04 浙江天宇药业股份有限公司 一种纯化替格瑞洛的方法
WO2019170244A1 (en) 2018-03-08 2019-09-12 Pharmaceutical Oriented Services Ltd. Ticagrelor—containing tablet formulation
EA202190328A1 (ru) 2018-07-27 2021-07-01 КРКА, д.д., НОВО МЕСТО Фармацевтическая композиция, содержащая тикагрелор
CN110194771A (zh) * 2019-05-08 2019-09-03 北京济美堂医药研究有限公司 一种替格瑞洛药用ii晶型的制备方法
CN114634489B (zh) * 2022-04-19 2023-07-04 奎马特里克斯有限公司 结晶形式

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
WO1997003084A1 (en) 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
ATE213245T1 (de) * 1996-12-20 2002-02-15 Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
WO1999005150A1 (en) * 1997-07-25 1999-02-04 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound

Also Published As

Publication number Publication date
EP1493745A1 (en) 2005-01-05
IL202582A0 (en) 2010-06-30
MY140674A (en) 2010-01-15
NZ522638A (en) 2004-06-25
MXPA02011795A (es) 2003-04-10
NO20025756D0 (no) 2002-11-29
EE200200665A (et) 2004-06-15
CN1247583C (zh) 2006-03-29
JP2014129423A (ja) 2014-07-10
BG66332B1 (bg) 2013-06-28
NO333289B1 (no) 2013-04-29
BR0111328A (pt) 2003-06-10
NO323780B1 (no) 2007-07-02
RU2010150799A (ru) 2012-06-20
EP1493745B1 (en) 2012-04-25
AU2001262874B2 (en) 2007-03-22
US20030181469A1 (en) 2003-09-25
AU2007200958A1 (en) 2007-03-29
EP1493745B2 (en) 2021-05-19
RU2418802C2 (ru) 2011-05-20
SK16852002A3 (sk) 2003-08-05
EE05222B1 (et) 2009-10-15
IS8825A (is) 2009-06-02
ES2259031T3 (es) 2006-09-16
PT1493745E (pt) 2012-06-28
IL152777A0 (en) 2003-06-24
IS2609B (is) 2010-04-15
PL359172A1 (en) 2004-08-23
EP2292622A1 (en) 2011-03-09
PT1289992E (pt) 2006-07-31
BG65837B1 (bg) 2010-02-26
CY1113047T1 (el) 2016-04-13
AU2007200958B2 (en) 2010-10-07
CN1817883A (zh) 2006-08-16
MY148652A (en) 2013-05-15
US20070173518A1 (en) 2007-07-26
BG110440A (bg) 2010-03-31
SG135965A1 (en) 2007-10-29
IS6623A (is) 2002-11-15
IS3019B (is) 2020-02-15
HUP1300386A2 (en) 2003-10-28
NO20120595L (no) 2003-01-24
HK1052347B (zh) 2006-09-08
US7265124B2 (en) 2007-09-04
JP5036947B2 (ja) 2012-09-26
ES2384708T3 (es) 2012-07-11
PH12011000127A1 (en) 2016-08-31
BG107331A (bg) 2003-07-31
WO2001092262A1 (en) 2001-12-06
DE60117972T2 (de) 2006-11-23
DE60117972D1 (de) 2006-05-11
GB0013407D0 (en) 2000-07-26
IL187482A (en) 2010-06-16
CZ307468B6 (cs) 2018-09-26
NO332306B1 (no) 2012-08-20
JP2012149093A (ja) 2012-08-09
HUP0302284A3 (en) 2007-05-29
ATE320430T1 (de) 2006-04-15
EP1289992B1 (en) 2006-03-15
NO20071547L (no) 2003-01-24
AU2010257449B2 (en) 2012-03-22
JP2003535092A (ja) 2003-11-25
PL392882A1 (pl) 2011-03-14
US20070293513A1 (en) 2007-12-20
NO20025756L (no) 2003-01-24
KR100781864B1 (ko) 2007-12-05
KR20030007829A (ko) 2003-01-23
CZ304347B6 (cs) 2014-03-19
BG111017A (bg) 2011-12-30
DK1289992T3 (da) 2006-07-03
HU229374B1 (en) 2013-11-28
RU2005127356A (ru) 2007-03-10
IL202582A (en) 2012-12-31
HK1073101A1 (en) 2005-09-23
CN1817883B (zh) 2011-10-05
SI1289992T1 (sl) 2006-08-31
JP5684192B2 (ja) 2015-03-11
AR068086A2 (es) 2009-11-04
CA2408596C (en) 2010-12-21
EP1289992A1 (en) 2003-03-12
AU2010257449A1 (en) 2011-01-20
SK287817B6 (sk) 2011-11-04
CZ20120293A3 (hu) 2003-07-16
IL152777A (en) 2008-11-26
RU2325391C2 (ru) 2008-05-27
DK1493745T3 (da) 2012-07-16
SI1493745T1 (sl) 2012-08-31
ZA200209324B (en) 2004-02-16
AR032335A1 (es) 2003-11-05
ATE555115T1 (de) 2012-05-15
HK1052347A1 (en) 2003-09-11
CN1432018A (zh) 2003-07-23
AU6287401A (en) 2001-12-11
CA2408596A1 (en) 2001-12-06
HU230471B1 (hu) 2016-07-28
UA73181C2 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
HUP0302284A2 (hu) Egy triazolo[4,5-d]pirimidin-vegyület új kristályos és amorf formái
HUP0105081A2 (hu) Triazolo[4,5-d]pirimidin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0002987A2 (hu) Cefdinir diciklohexil-amin sója és eljárás a só előállítására valamint a vegyület sójából történő felszabadítására
HUP0004333A2 (hu) Új triazolo [4,5-d] pirimidin-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
SE9701398D0 (sv) Novel compounds
MXPA03010630A (es) Nuevos derivados de pirrol como agentes farmaceuticos.
AU2002357773A1 (en) 1,6 naphthyridines useful as inhibitors of syk kinase
HUP0204246A2 (hu) Új tiazolo[4,5-d]pirimidin-származékok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
SE9702001D0 (sv) Novel compounds
HUP0302519A2 (hu) Az atorvasztatin kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE502932T1 (de) Makrocyclische analoga und verfahren zu ihrer verwendung und herstellung
HUP0402336A2 (hu) Tieno[2,3-d]pirimidin-2,4-dion-származékok, eljárás előállításukra, alkalmazásuk autoimmun betegségek modulálására és a vegyületeket tartalmazó gyógyszerkészítmények
NO993027D0 (no) Pyrrolo[3,4-D]pyrimidinonderivater og deres anvendelse som legemidler
AU2003288869A1 (en) PYRAZOLO (3,4-d) PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF H.PYLORI INFECTION
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
HUP0303737A2 (hu) 6-helyzetben szubsztituált indolinonok és alkalmazásuk kináz inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
ATE251162T1 (de) Triazolo(4,5-d)pyrimidin-verbindungen
NO20000965L (no) FremgangsmÕte for fremstilling av veksthormon-utskillende forbindelser
PL359727A1 (en) Crystalline pharmaceutical
SE0100297D0 (sv) New compounds
HUP0004621A2 (hu) Egy HIV proteáz inhibitor fokozott orális felszívódást és biológiai hozzáférhetőséget mutató szulfátsója
HUP0203476A2 (en) Sodium 2-(4,6-dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionate, use thereof and pharmaceutical composition containing the same
AU2002340862A1 (en) Process for the preparation of crystalline cefuromixe axetil
ECSP972213A (es) Derivados 6,6 o 6,7- biciclicos sustituidos que contienen pirido o pirimido